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Background: The aim of this study was to explore oxidative
stress status, especially the enzyme myeloperoxidase in
children with end-stage renal disease. Also, we investigat-
ed possible associations between the atherogenic index of
plasma and these parameters. 
Methods: Lipid status parameters, oxidative stress status
parameters, and myeloperoxidase concentration were
measured in the sera of 20 children in the last stage of
chronic renal disease (ESRD) and 35 healthy children of
matching age and sex. The Atherogenic Index of Plasma
(AIP) was calculated according to the appropriate equa-
tion. 
Results: We did not find any significant differences in
myeloperoxidase concentrations between the investigated
groups (p=0.394). Oxidative stress parameters were, how-
ever, significantly higher in the patient group (p<0.001), as
well as the atherogenic index of plasma (p<0.001). Myelo -
per oxidase concentration and advanced oxidation protein
product (AOPP) concentration were independently associ-
ated with increased AIP in the patient group (p<0.05). 
Conclusions: Changes in AIP in children with ERSD are
associated with the oxidative stress status and myeloper -
oxidase concentration.
Keywords: myeloperoxidase, oxidative stress, chronic
kidney disease
Kratak sadr`aj
Uvod: Cilj ove studije bio je da se ispita status oksidativnog
stresa, naro~ito enzima mijeloperoksidaze kod dece u ter -
mi nalnoj fazi bubre`ne insuficijencije. Tako|e smo istra -
`ivali potencijalnu povezanost izme|u aterogenog indeksa
plazme i ovih parametara. 
Metode: Parametri lipidnog statusa, parametri statusa oksi -
dativnog stresa i koncentracija mijeloperoksidaze mereni su
u serumu 20 dece u finalnoj fazi hroni~ne bubre`ne insu -
ficijencije (HBI) i 35 zdrave dece odgovaraju}eg uzrasta i
pola. Aterogeni indeks plazme (AIP) izra~unat je pomo}u
odgovaraju}e jedna~ine. 
Rezultati: Izme|u ispitivanih grupa nisu otkrivene zna~ajne
razlike u koncentracijama mijeloperoksidaze (p=0,394).
Me|utim, parametri oksidativnog stresa bili su zna~ajno vi{i
u grupi obolelih (p<0,001) kao i aterogeni indeks plazme
(p<0,001). Koncentracija mijeloperoksidaze i kon centra -
cija proizvoda uznapredovale proteinske oksida cije (eng.
AOPP) bili su nezavisno povezani sa povi{enim AIP-om u
grupi obolelih (p<0,05). 
Zaklju~ak: Promene u AIP-u kod dece sa HBI povezane su
sa statusom oksidativnog stresa i koncentracijom mijelo -
pero ksidaze. 
Klju~ne re~i: mijeloperoksidaza, oksidativni stres, hro -
ni~na bubre`na insuficijencija
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Introduction
Cardiovascular disease is the main cause of mor-
tality in hemodialysis patients, but the exact cause of
cardiovascular damage is still unclear (1). Despite an
improvement in the survival of children with severe
chronic kidney disease, the risk of death due to car-
diovascular disease (CVD) in children with end-stage
renal disease (ESRD) is higher than in the general
pediatric population (2). Emerging evidence suggests
that, besides the traditional risk factors, a combina-
tion of chronic inflammation and oxidative stress may
have an essential role in the development of cardio-
vascular abnormalities in hemodialysis (HD) patients
(1–4). 
It is well known that endothelial dysfunction plays
a central role in the initiation of atherosclerosis (5).
Oxidative modifications of low density lipoprotein parti-
cles (LDL) are among the main steps in atherosclerot-
ic plaque formation. Evidence exists suggesting that
the atherosclerotic process begins in childhood and the
extent of early atherosclerosis is directly associated with
the levels of lipoproteins, blood pressure, and obesity in
childhood and adolescence (2). Also, it is known that
hemodialysis (HD) treatment itself contributes to the
increased oxidative stress in the patients and leads to
chronic inflammation in ESRD (4). 
Myeloperoxidase (MPO), an oxidative enzyme
present in leukocyte azurophilic granules released
during inflammation, causes irreversible protein and
lipid modifications. Recent studies have shown that
higher levels of MPO-mediated endothelial dysfunc-
tion could represent a link between oxidative stress,
inflammation, and cardiovascular disease (6). How -
ever, the role of MPO in the protogenesis of chronic
kidney disease (CKD), as well as its link to chronic kid-
ney disease, though not novel (1–5), remain insuffi-
ciently investigated in the pediatric population. 
In renal pathology, dyslipidemia presents one of
the traditional risk factors, primarily characterized with
increased triglycerides (TG) and reduced high-density
lipoprotein (HDL-C) concentration. Loga rith mic
ration of TG and HDL-C, known as the atherogenic
index of plasma (AIP) has been successfully used as
an additional index in the assessment of atheroscle-
rosis progression (7, 8). The aim of this study was to
investigate associations between AIP levels and
MPO concentration, since MPO activity is an impor-
tant contributor to the development of athe ro scle -
rosis. To the best of our knowledge, such associations
have not been sufficiently explored. 
Materials and Methods
Subjects
The study group consisted of 20 children with
ESRD, all of them undergoing HD at the Hemo -
dialysis Unit of the University Children’s Hospital in
Belgrade. The control group consisted of 35 age and
gender matched healthy children (Table I). The study
protocol included height and weight measurement
for body-mass index calculation (BMI) and waist and
hip measurement for waist-to-hip ratio (WHR) (Table
I). Systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were measured at least 3 times and
the presence of hypertension was defined as SBP
exceeding the 95th percentile of SBP values in
healthy children (9) (Table I). All children and their
parents gave consent prior to enrolment in our study
(as required by the ethical guidelines laid down by the
Declaration of Helsinki). The institutional review com-
mittees of the University Children’s Hospital and the
Faculty of Pharmacy, both in Belgrade, approved our
study. 
The HD patients were dialyzed 3.5–4 h, three
times per week, with polysulfone dialyzers (Fresenius
Medical Care, Bad Hamburg, Germany). Unfractio -
nated heparin was used during HD procedures. The
etiologies of underlying CKD were: congenital anom-
alies of the kidney and urinary tract (10), focal seg-
mental glomerulosclerosis (4), atrophic pyelonephritis
(4), and nephritic syndrome (2). HD patients had a
mean duration of dialysis treatment of 3.8±1.1 years.
No patient received drugs that could interfere with
oxidative stress. All patients were normotensive.
Exclusion criteria for patients were infection, vasculi-
tis, and respiratory or hepatic diseases. 
Samples
Blood samples were obtained after overnight
fasting for both controls and patients. Serum and
plasma were immediately separated and stored at
–80 °C in aliquots until analysis. 
Analytical methods
Leukocytes were determined by a combination of
flow impedance and light absorbance using a Pentra
60C+ analyzer (Horiba ABX, Montpelier, France). 
High sensitivity serum CRP (hsCRP) levels were
measured by the latex-enhanced immunoturbidimet-
ric method (Quantex hsCRP kit, BIOKIT, Barcelona,
Spain) on an ILab 600 analyzer (Instrumentation
Labo ratory, Milan, Italy). Fibrinogen was measured in
citrate plasma using the Clauss method on an ACL
200 (Instrumentation Laboratory) using original
reagents (10). 
Total cholesterol (TC) and TG were analyzed by
routine enzymatic methods using an ILab 300+ ana-
lyzer (Instrumentation Laboratory, Milan, Italy) and
Randox Laboratories (Armdore, UK) reagents. HDL-C
was measured using the same method by precipitating
plasma with phosphotungstic acid in the presence of
magnesium ions. Apolipoprotein A-I (apoA-I) and apo -
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lipoprotein B (apoB) were measured by immuno -
turbidimetry using an ILab 600 analyzer and Dialab
(Vienna, Austria) reagents. The concentration of LDL
cholesterol (LDL-C) was calculated using the original
equation of the Friedewald formula (11). 
In order to determine the level of lipid peroxida-
tion, we measured MDA plasma concentration as
thiobarbituric acid-reacting substances using the
method previously described by Girotti (12). The rate
of nitro blue tetrazolium reduction was used to mea -
sure the plasma level of superoxide anion (O2
.-) pro-
duction as a marker of oxidative stress using the
method of Auclair and Voisin (13). Plasma superoxide
dismutase (SOD) activity was measured according to
the method published by Misra and Fridovich (14).
One unit of SOD activity is defined as the activity that
inhibits the autooxidation of adrenalin by 50%. The
plasma advanced oxidation protein products (AOPP)
concentration was determined using the method of
Witko-Sarsat et al. (15). Briefly, AOPP were measured
in acidic conditions at 340 nm in the presence of po -
tassium iodide and the concentration was expressed
as chloramine-T equivalents (mmol Hloramin T
Equiv./L) (15). Determination of serum paraoxonase
1 (PON1) status involved measurement of PON1
activity to wards two substrates: paraoxon (POase
activity) and dia zoxon (DZOase activity). Paraoxon
PON1 and diazoxon hydrolysis rates were measured
spectro photometrically in serum using a continuous
reading spectro photometer (Pharmacia LKB, Cam -
bridge, UK) according to Richter and Furlong (16).
Popu lation distribution plots of diazoxonase versus
para oxonase activities provide PON1 phenotypes:
PON1192QQ, PON1192QR, and PON1192RR
(16). PON1 Q192R polymorphism affects the catalyt-
ic efficiency of PON1 towards some of its substrates:
PON1192QQ isoform hydrolyzes diazoxon rapidly as
compared to R192 isoform, while PON1192RR iso-
form hydrolyzes paraoxon rapidly as compared to
PON1 Q192 isoform (16). 
MPO concentration was assayed by using the
two-site sandwich Elisa assay (Immundiagnostik AG,
Bensheim, Germany), following the manufacturer’s
instructions. The absorbance was measured using an
ELISA reader (Pharmacia LKB, Cambridge, UK) at
450 nm against 620 nm as a reference. 
The Atherogenic Index of Plasma (AIP) was cal-
culated according to the following equation:
AIP=log(TG/HDL-C), with units for TG and HDL-C in
mmol/L (8). 
Statistical analysis
Values were expressed in two ways, either as
means ± standard deviations (SD) for normally dis-
tributed variables or as geometrical means and the
95% confidence intervals if distribution was log-nor-
mal. Comparisons of continuous variables were per-
formed using the Student’s t-test. Categorical vari-
ables are shown as relative or absolute frequencies.
Analysis of categorical variables was performed using
the Chi-square test for contingency tables. 
To estimate the correlation between the exam-
ined parameters of lipid profile and oxidative stress
and AIP, we performed Spearman’s correlation analy-
sis. Spearman’s rho correlation test was used for
screening the independent variables. If P-values for
Spearman’s rho coefficient of correlation were< 0.10,
the variables were included in further regression
analyses. We used univariate regression analysis to
estimate significant independent association of the
investigated parameters with AIP. Further statistical
analysis referred to multiple regression analysis. The
tolerance option was used to prevent multicollinearity
among the independent variables (17). All statistical
analyses were performed using PASW Statistics ver-
sion 18.0 and MedCalc Software version 11.4. All
statistical tests were considered significant at the 0.05
probability level. 
Results
General demographic and anthropometric
parameters are presented in Table I. We have noticed
significantly higher waist-hip-ratio (WHR), as well as
SBP and DBP in patients than in healthy children,
while BMI value was significantly lower in the patient
group (Table I). 
Biochemical parameters, oxidative stress and
antioxidative defense parameters in both children
with ESRD (patients) and healthy children are pre-
sented in Table II. Concentrations of TG and total
WBC count were significantly higher in the group of
patients, while concentrations of HDL–C and LDL–C
were significantly lower compared with healthy chil-
dren (Table II). Also, we found higher parameters of
oxidative stress, AOPP and MDA, in the patient group.
Both PON1 enzyme activities, DOase and POase,
were lower in the patient group, but only POase was
significantly lower. Furthermore, the difference was
statistically significant only for POase activities (Table
II). As expected, both SOD activity and AIP were sig-
nificantly higher in the patient group (Table II). 
Table III shows Spearman’s non-parametric cor-
relations between AIP and biochemical parameters,
as well as the parameters of oxidative stress in HD
and healthy children. 
If P-values for Spearman’s rho coefficient of cor-
relation were less than 0.1, the variables were consid-
ered for further regression analysis. BMI, DBP, AOPP
and MPO concentrations all have a significantly posi-
tive correlation with AIP. Only MPO showed a positive
correlation in both healthy children and the patient
group (Table III). 
In order to avoid multicollinearity and to provide
the correct model for parameters investigation, we per -
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Table I Demographic and anthropometric data in patients and control group.
Data are expressed as mean ± SD; *- means and 95th confidence intervals derived from log-normal values
1 Continuous variables were compared using Student’s t test and categorical variables by Chi-square test.
BMI – Body Mass Index; WHR – Waist to Hip Ratio; SBP – Systolic Blood Pressure; DBP – Diastolic Blood Pressure
Data are expressed as mean ± SD; *- means and 95th confidence intervals derived from log-normal values
1Continuous variable were compared using Student’s t test and categorical variables by Chi-square test.
TC – Total Cholesterol; LDL – Low Density Lipoprotein; HDL – High Density Lipoprotein; TG – Triglycerides; AIP – Atherogenic
Index of Plasma; WBC – White Blood Cell; MPO – Myeloperoxidase; AOPP – Advanced Oxidation Protein Products; SOD –





Gender (m/f) 19/16 9/11 0.702
Age (years) 12.2±2.51 12.7±5.72 0.659
BMI  (kg/m2) 18.8±3.33 16.5±2.85 < 0.05
WHR 0.8±0.04 0.9±0.06 < 0.001
Duration of dialysis (years) - 3.8±1.1 -
SBP (mmHg) 112.0±9.2 127.2±22.3 < 0.001
DBP (mmHg) 71.3±7.4 78.2±20.1 < 0.05
Table II Clinical and laboratory parameters, OS/antioxidative defense parameters, PON1 activities and PON1 phenotypes dis-





TC  (mmol/L) 4.5±0.84 4.2±1.18 0.344
LDL-C (mmol/L) 2.7±0.63 2.2±0.65 < 0.05
HDL-C (mmol/L) 1.4±0.35 1.2±0.52 < 0.05
TG* (mmol/L) 0.7 (0.602–0.801) 1.7 (1.381–2.177) <0.001
AIP -0.3±0.188 0.2±0.307 < 0.001
Total protein (g/L) 69.8±4.06 63.6±7.54 < 0.001
WBC (103/mm3) 6.8±1.63 8.2±3.39 < 0.05
MPO (mg/L) 57.1±15.44 66.6±6.31 0.394
MDA  (μmol/L) 1.2±0.39 1.8±0.34 < 0.001
O2
- (mmol/min/L) 164.5±69.52 156.3±83.22 0.701
AOPP (mmol/L) 12.4±3.84 27.9±41.9 < 0.001
SOD (kU/L) 104.9±28.6 128.1±35.61 < 0.05
SH-groups (g/L) 0.5±0.05 0.5±0.13 0.827
POase (U/L) 435.2±91.91 232.2±86.53 < 0.05
DZOase (U/L) 10581±4081 9354.9±2337.5 0.372
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Table III Spearman’s non-parametric correlations between AIP and biochemical and oxidative status parameters for the two
study groups.
#Variables with p<0.10 were entered in multiple logistic regression analysis
BMI – Body Mass Index; WHR – Waist to Hip Ratio; TC – Total Cholesterol; LDL – Low Density Lipoprotein; HDL – High Density
Lipoprotein; TG – Triglycerides; AIP – Atherogenic Index of Plasma; SBP – Systolic Blood Pressure;  DBB – Diastolic Blood
Pressure; WBC – White Blood Cell; MPO – Myeloperoxidase; AOPP – Advanced Oxidation Protein Products; SOD – Superoxide
Dismutase; SH-groups – Sulfhydryl groups; POase – Paraoxonase activity; DZOase – Diazoxonase activity
Parameter
Controls Patients
r p r p
BMI (kg/m2) -0.09 0.607 0.467 <0.05#
WHR 0.240 0.164 -0.182 0.470
SBP (mmHg) -0.328 0.082 0.422 0.064#
DBP (mmHg) -0.169 0.309 0.540 <0.05#
Glucose (mmol/L) 0.023 0.895 0.122 0.609
TC (mmol/L) 0.076 0.666 0.160 0.499
LDL-C (mmol/L) 0.142 0.417 0.007 0.977
MPO (mg/L) 0.360 <0.05 0.595 <0.001#
MDA  (mmol/L) 0.197 0.287 0.394 0.096#
O2
- (mmol/min/L) -0.307 0.102 0.433 0.064#
AOPP (mmol/L) -0.397 0.057 0.744 <0.001#
SOD (kU/L) -0.085 0.634 -0.019 0.937
SH-groups (g/L) -0.391 0.385 -0.307 0.265
POase (U/L) -0.179 0.320 -0.067 0.853
DZOase (U/L) 0.126 0.486 0.515 0.128#
b SE (b) P R2 adjusted R2
MPO (mg/L) 0.515 0.001 <0.05 0.266 0.225
MDA  (mmol/L) 0.407 0.198 0.084 0.165 0.116
O2
- (mmol/min/L) 0.469 0.001 0.043 0.220 0.174
AOPP (mmol/L) 0.691 0.003 <0.001 0.478 0.447
Table IV Linear regression analysis for the association of investigated parameters with the Atherogenic Index of Plasma (AIP)
in patients (univariate analyses).
AIP
R2 = 0.532
adjusted R2 = 0.365
b SE (b) P
BMI (kg/m2) 0.243 0.025 0.320
Dialysis duration (months) 0.089 0.002 0.702
SBP (mmHg) 0.087 0.004 0.781
DBP (mmHg) -0.264 0.005 0.425
MPO (mg/L) 0.503 0.001 <0.05
Table V Multiple regression analysis for the association of investigated parameters with the Atherogenic Index of Plasma (AIP)
in patients. 
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formed a univariate regression analysis in the patient
group (Table IV). MPO and AOPP concentrations
showed independent association with AIP (Table IV). 
In order to further investigate the independent
influence of MPO and AOPP on AIP, we performed a
multiple regression analysis. We made two models,
one for MPO investigation and another for AOPP
(Table V, Table VI). In accordance with the results of
Spearman’s correlation analysis, we included BMI,
duration of dialysis, SBP, DBP in both models (Table
IV, Table VI). 
The obtained results confirmed our prediction.
MPO and AOPP concentrations were independently
associated with increased AIP (Table V, Table VI). In
fact, 36.5% of the AIP increase in patients could be
explained by MPO and even 55.5% of AIP changes
could be explained by the increase in AOPP concen-
trations in the patients. 
Discussion
It is well known that pediatric renal diseases are
associated with a significant rise in CVD risk (3).
Prevention of atherosclerosis and CVD in the pediatric
population is of particular importance because chil-
dren with chronic kidney disease are an extremely vul-
nerable group. Therefore, the discovery of a new reli-
able marker for early detection of the origin and
development of CVD risk in ESRD patients is of great
medical importance. 
Dyslipidemia, including increased LDL-C, TG
and decreased HDL-C and ApoAI levels, in ESRD is
the most important risk factor for atherosclerosis (18,
19). Expectedly, elements of dyslipidemia were also
present in our patient group (Table II). Generally, dys-
lipidemia develops as a consequence of unbalanced
energy metabolism and adiposity. We have shown
differences in the markers of adiposity between our
exam inees. BMI was significantly reduced, while
WHR was increased in the group of patients (Table I).
In people with established renal disease, there is con-
troversy regarding the parameter which would most
accurately reflect adiposity. Evaluation of BMI in CKD
has yielded conflicting results (20, 21). Children with
kidney diseases may have lower BMI due to reduction
of the muscle mass which is associated with greater
cardiovascular risk. According to INTERHEART study,
WHR has stronger predictive power for cardiovascular
events than BMI (20). Accordingly, it has been shown
that in children on HD, normal or low BMI and elevat-
ed WHR may indicate a greater risk of cardiovascular
disease development (22), and such findings are con-
sistent with our results (Table I). BMI in our patients
was even lower than in control group, but elevated
WHR pointed toward increased CVD risk. 
Beside traditional risk factors such as hyperten-
sion and dyslipidemia, OS may play an important role
in the pathogenesis of CVD (3). Hemodialysis repre-
sents a therapeutic procedure in patients with renal
impairment, but it is believed that dialysis leads to
chronic inflammation caused by the activation of
phagocytes. Hemobioincompatibility depends on the
nature of the dialysis membrane, as well as of the
possible endotoxin contamination of dialysate.
Activated neutrophils and monocytes lead to the for-
mation of reactive intermediates which contribute to
the oxidative unbalance and develop oxidative stress
in which myeloperoxidase plays an important role
(23).
Therefore, it has been proposed that HD can be
considered a human model of OS. Our results fit in
such a hypothesis, since our HD patients exhibited
significantly higher OS, as reflected by elevated MDA
and AOPP levels. Witko-Sarsat et al. (15) investigated
a link between MPO and monocyte activation in
patients with chronic renal failure. They came to the
conclusion that the AOPP are capable of releasing
inflammatory mediators and thus represent a new
class of inflammatory mediators and markers of
oxidative stress (15). 




adjusted R2 = 0.555
b SE (b) P
BMI (kg/m2) 0.266 0.021 0.582
Dialysis duration (months) -0.121 0.002 0.567
SBP (mmHg) 0.038 0.004 0.888
DBP (mmHg) -0.266 0.004 0.354
AOPP (mmol/L) 0.658 0.003 0.002
Conditions that are accompanied by OS and
inflammation are usually associated with reduced
activity of paraoxonase (PON1). PON1 is an antioxi-
dant enzyme located on the HDL particle (24). In
addition to its antioxidant role, PON1 shows anti -
atherogenic properties by preventing the formation of
foam cells, through reducing the influx of cholesterol
and oxidized lipids and inhibiting macrophage choles-
terol synthesis (25). PON1 activity is reduced in
patients with renal diseases. Although some studies
showed the benefits of HD via increasing the antiin-
flammatory activity of HDL, other researches showed
no differences in PON1 related to HD. Furthermore,
several studies even demonstrated reduction in PON1
activity in patients on HD (24, 26). Our results
showed lower PON1 activity in children on HD as
compared with controls (Table II). Lower POase activ-
ity of PON1 in nephrology patients could arise as a
result of partial inactivation of the enzyme due to
increased oxidative stress, which was evident among
the patients in our study (Table II). 
Surprisingly, we found no differences in MPO
concentrations between children on HD and their
healthy counterparts (Table II). So far, little data has
been reported on the changes of MPO levels in chil-
dren on HD. Lack of significant differences between
the healthy and HD groups in our study could be a
consequence of the relatively small sample size, but
also of the younger age of our examinees and lower
intensity of inflammation, as demonstrated by the
total WCB count (Table II). 
Next, we examined associations of changes in
lipid profile and oxidative stress in children on HD
treatment with AIP. Previously, AIP was proposed as a
new possible marker that can be used for detection of
early atherosclerosis. In recent years, this parameter
has started to gain importance as an indicator of ath-
erosclerosis (27, 28). It has been suggested that AIP
is less susceptible to variations in disease activity dur-
ing longer periods of time. This makes it more attrac-
tive for use in cardiovascular risk prediction than lipid
concentrations per se, especially in children with
ESRD (8). Elevated AIP is connected with higher per-
cent of remnant lipoproteins and small, dense LDL
(sdLDL) particles (29, 30). The impaired HDL com-
position, increased serum levels of remnant lipopro-
teins, reduced levels of very low density and interme-
diate density lipoproteins, and increased sdLDL are
the features of an atherogenic lipid profile in children
with ESRD (30). When compared to larger LDL sub-
classes, sdLDL particles are easily taken up by arterial
tissue and are much more prone to oxidation which
altogether can lead to accelerated plaque formation.
Therefore, elevated AIP might reflect the presence of
remnant lipoproteins and sdLDL levels (30). Also, in
our research, AIP was in significant positive correla-
tion with MPO in both controls and patient group
(Table III), reflecting the cooperative effects of dyslipi-
demia, OS, and inflammation in the onset and pro-
gression of atherosclerosis. Previous studies have de -
monstrated that HD treatment increases the produc-
tion of MPO from azurophilic granules. Also, it has
been shown that MPO prolongs the life span of neu-
trophils by suppressing the constitutive cell death pro-
gram. In this way, MPO may extend inflammation
(31, 32). Additionally, the revealed independent asso-
ciations between MPO and AIP in our study (Table V)
raised a possibility of more profound involvement of
MPO in the metabolic alterations of lipoprotein distri-
bution. 
AIP is a simple and practical ratio which can be
easily estimated and used to further stratify athero-
genic risk in subjects who may have an apparently
normal lipid profile according to other parameters.
Having in mind the simplicity of determining AIP, we
further tried to identify the pattern and predictors of
an abnormal AIP in children on HD. According to our
results, the AIP correlated with BMI, DBP, AOPP, and
MPO (Table III). Stepwise multiple linear regression
analysis was carried out to determine the significant
predictors of AIP. We found that MPO and AOPP are
independently associated with AIP (Table IV, Table V,
respectively). On the basis of the foregoing facts, we
hypothesize that AIP should be routinely analyzed
from the beginning of HD treatment because it can
indirectly reflect the degree of oxidative stress caused
by the release of MPO and the resulting increase in
AOPP. Our results have shown that the AIP level is not
dependent on the duration of HD; however, it is
strongly influenced by the oxidative enzyme MPO and
its products. 
In conclusion, our results demonstrated elevated
OS, inflammation, and patterns of dyslipidemia in
children with ESRD, indicating elevated CVD risk in
this group. AIP was independently associated with
MPO and AOPP, suggesting firm connections
between lipid disorders, inflammation, and OS in this
category of patients. Also, AIP emerged not only as a
hallmark of dyslipidemia, but also as a quickly acces-
sible marker of the interplay between several patho-
physiological processes involved in the elevation of
CVD risk in children with ESRD. Future cohort studies
are needed to evaluate our present findings. 
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